Results 181 to 189 of about 14,564 (189)

A phase II study of aflibercept in patients with advanced epithelial ovarian cancer and symptomatic malignant ascites

Gynecologic Oncology, 2012
Nicoletta Colombo, Giorgia Mangili, Serafina Mammoliti   +2 more
exaly  

Evaluation of pain during intravitreal aflibercept injections

European Journal of Ophthalmology, 2018
Merve Inanç, Pelin Yilmazbas
exaly  

Subfoveal Choroidal Thickness during Aflibercept Therapy for Neovascular Age-Related Macular Degeneration

Ophthalmology, 2016
Hideki Koizumi, Mariko Kano, Masaaki Saito   +2 more
exaly  

Intravitreal aflibercept 8 mg in neovascular age-related macular degeneration (PULSAR): 48-week results from a randomised, double-masked, non-inferiority, phase 3 trial

Lancet, The
W Lloyd Clark, Alyson J Berliner, Ursula Schmidt-Ott   +2 more
exaly  

A pharmacoepidemiologic study of ranibizumab and aflibercept use 2013–2016. The Fight Retinal Blindness! Project

Graefe's Archive for Clinical and Experimental Ophthalmology, 2018
Daniel Barthelmes, Vuong Nguyen, Richard Walton   +2 more
exaly  

Intravitreal aflibercept 8 mg in diabetic macular oedema (PHOTON): 48-week results from a randomised, double-masked, non-inferiority, phase 2/3 trial

Lancet, The
David S Boyer, Hani Salehi-Had, András Seres   +2 more
exaly  

Aflibercept

Nature Reviews Drug Discovery, 2012
Michael W. Stewart, Seden Grippon, Peter Kirkpatrick   +2 more
openaire   +1 more source

Outcomes of Treatment-Resistant Neovascular Age-Related Macular Degeneration Switched from Aflibercept to Faricimab

Ophthalmology Retina
Raffaele Raimondi, Deepali Varma, Maged Habib   +2 more
exaly  

Aflibercept

Reactions Weekly, 2014
openaire   +1 more source